High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
29.83M
-43.5%
-0.590
-4.88%
27.83M
-14.98%
-0.624
-5.41%
28.28M
-35.16%
-0.643
+56.8%
Estimates Revision
The market is revising Downward the revenue expectations for Xencor, Inc. (XNCR) for FY2025, with the revenue forecasts being adjusted by -6.04% over the past three months. During the same period, the stock price has changed by 112.16%.
Revenue Estimates for FY2025
Revise Downward
-6.04%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-28.6%
In Past 3 Month
Stock Price
Go Up
+112.16%
In Past 3 Month
11 Analyst Rating
Wall Street analysts forecast XNCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XNCR is 24.00 USD with a low forecast of 6.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
1 Hold
1 Sell
Moderate Buy
Current: 18.140
Low
6.00
Averages
24.00
High
42.00
Current: 18.140
Low
6.00
Averages
24.00
High
42.00
Truist
NULL -> Buy
initiated
$29
2025-11-24
Reason
Truist
Price Target
$29
2025-11-24
initiated
NULL -> Buy
Reason
Truist initiated coverage of Xencor with a Buy rating and $29 price target. Lead program, TL1A, has early data suggesting potential for sustained target engagement and the company's broader immunology and inflammation pipeline leverages Xencor's expertise in T-cell engagers, supported by its "deep oncology roots" and prior validation through xaluritamig, the analyst tells investors.
JPMorgan
Overweight -> Overweight
downgrade
$20 -> $18
2025-11-06
Reason
JPMorgan
Price Target
$20 -> $18
2025-11-06
downgrade
Overweight -> Overweight
Reason
JPMorgan lowered the firm's price target on Xencor to $18 from $20 and keeps an Overweight rating on the shares following the Q3 report.
Cantor Fitzgerald
NULL -> Overweight
maintain
$40 -> $42
2025-11-06
Reason
Cantor Fitzgerald
Price Target
$40 -> $42
2025-11-06
maintain
NULL -> Overweight
Reason
Cantor Fitzgerald raised the firm's price target on Xencor to $42 from $40 and keeps an Overweight rating on the shares. By this time next year, Cantor expects Xencor could have a recommended Phase 3 dose identified for two different T-cell engage antibodies, with Phase 3s both starting in 2027, as well as a Phase 2b UC study of long-acting TL1A antibody '942 largely or even fully enrolled, the analyst tells investors in a research note.
Barclays
Etzer Darout
Underweight -> Overweight
upgrade
$6 -> $23
2025-10-29
Reason
Barclays
Etzer Darout
Price Target
$6 -> $23
2025-10-29
upgrade
Underweight -> Overweight
Reason
Barclays analyst Etzer Darout double upgraded Xencor to Overweight from Underweight with a price target of $23, up from $6. The firm has a more positive outlook on the company's pipeline following updates at the AACR-NCI-EORTC Conference. XNCR's recent updates for XmAb819, a first-in-class ENPP3 x CD3 bispecific T-cell engager in development for advanced clear cell renal cell carcinoma, and XmAb541 in CLDN6+ tumors were positive and exceeded expectations, the analyst tells investors in a research note. Barclays now values these programs at $6 per share.
RBC Capital
Gregory Renza
Outperform
maintain
$15 -> $18
2025-10-27
Reason
RBC Capital
Gregory Renza
Price Target
$15 -> $18
2025-10-27
maintain
Outperform
Reason
RBC Capital analyst Gregory Renza raised the firm's price target on Xencor to $18 from $15 and keeps an Outperform rating on the shares. The firm cites the company's phase 1 data on XmAb819 anti-ENPP3/anti-CD3 bispecific antibody in ccRCC at the AACR-NCI-EORTC conference, noting that its 25% Objective Response Rate in heavily pretreated patients is indicative of a drug that can compete on efficacy, while the manageable CRS - Cytokine Release Syndrome - with a generally well-tolerated profile should enable broad use and potential for outpatient administration, the analyst tells investors in a research note.
BofA
Neutral
maintain
$14 -> $15
2025-10-27
Reason
BofA
Price Target
$14 -> $15
2025-10-27
maintain
Neutral
Reason
BofA raised the firm's price target on Xencor to $15 from $14 and keeps a Neutral rating on the shares after the company shared results from XmAb819 in a Phase 1 dose escalation study in ccRCC at the Triple Meeting. The firm, which sees promise in the pipeline but sees early dose escalation readouts as unlikely to be conclusive, updated its model to increase peak penetration for XmAb819 to 15% from 13% and probability of success from 18% to 22%, the analyst noted.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Xencor Inc (XNCR.O) is -7.20, compared to its 5-year average forward P/E of -2.16. For a more detailed relative valuation and DCF analysis to assess Xencor Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.16
Current PE
-7.20
Overvalued PE
32.37
Undervalued PE
-36.68
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
11.70
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
81.04
Undervalued EV/EBITDA
-57.65
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
14.61
Current PS
0.00
Overvalued PS
20.78
Undervalued PS
8.45
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 160.17% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 160.17% over the last month.
Sold
Bought
XNCR News & Events
Events Timeline
(ET)
2025-11-05
16:03:09
Xencor Announces Q3 Earnings Per Share of 8 Cents, Below Consensus Estimate of 70 Cents
2025-10-27 (ET)
2025-10-27
08:45:33
Xencor unveils preliminary findings for XmAb819
2025-05-07 (ET)
2025-05-07
16:16:57
Xencor sees 2025-end cash at $535M-$585M
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/897780c1b14748afce8607709779b7fc96a30d59f8f5a4ea220877ed701cad69.jpeg)
Preview
4.0
11-07BenzingaJP Morgan Keeps Overweight Rating on Xencor, Reduces Price Target to $18
Preview
4.0
11-07BenzingaRBC Capital Reaffirms Outperform Rating for Xencor and Increases Price Target to $19
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/0bb4cbf5b5cc7a2e3d977599f8229230b3f2be2899d76ce5ac1747c55529aa66.png)
Preview
9.0
10-28Yahoo FinanceCould Xencor's (XNCR) Preliminary Cancer Findings Indicate a New Advantage in Its Innovation Approach?
Sign Up For More News
People Also Watch
FAQ
What is Xencor Inc (XNCR) stock price today?
What is Xencor Inc (XNCR)'s business?
What is the price predicton of XNCR Stock?
What is Xencor Inc (XNCR)'s revenue for the last quarter?
What is Xencor Inc (XNCR)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Xencor Inc (XNCR)'s fundamentals?
How many employees does Xencor Inc (XNCR). have?